Tularemia - Pipeline Insight, 2024

This “Tularemia - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Tularemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tularemia: Understanding

Tularemia: Overview

Tularemia, also known as "rabbit fever," is a zoonotic disease caused by the bacterium Francisella tularensis. This highly infectious disease can affect various organ systems in the body, including the skin, eyes, throat, lungs, and intestines, depending on the route of infection. Tularemia is typically acquired through contact with infected animals, such as rodents and rabbits, or through the bites of infected arthropods like ticks and deer flies. Additionally, the disease can be contracted by handling contaminated animal tissue, inhaling aerosolized bacteria, or consuming contaminated food and water. The severity of tularemia varies greatly, ranging from mild and self-limiting cases to severe and potentially life-threatening complications.

There are four recognized subspecies of F. tularensis, with type A causing the most severe disease in North America and type B associated with a milder form in Europe and Asia. Tularemia can present in several ways, such as ulceroglandular, glandular, oculoglandular, oropharyngeal, gastrointestinal, respiratory, and typhoidal forms, depending on the mode of transmission. The organism can survive in extreme conditions and has been found in many insects and animals, with mosquitoes serving as a vector in Northern Europe and ticks in North America. Certain populations, including veterinarians, laboratory workers, farmers, landscapers, and those who work with animals or handle meat, are at increased risk of infection.

Tularemia can present with a wide range of signs and symptoms depending on the route of infection and the specific form of the disease. The most common form is ulceroglandular tularemia, which typically begins with a skin ulcer at the site of infection, often accompanied by painful and swollen lymph nodes, fever, chills, headache, and fatigue. Oculoglandular tularemia affects the eyes, causing symptoms such as eye pain, swelling, discharge, redness, light sensitivity, and the formation of ulcers inside the eyelid, along with tender lymph nodes around the ear, neck, and jaw. Oropharyngeal tularemia, often caused by consuming contaminated food or water, can lead to a sore throat, mouth ulcers, tonsillitis, and swollen lymph nodes in the neck.

Treatment for tularemia primarily involves the use of antibiotics, with streptomycin being the drug of choice, although gentamicin is also an acceptable alternative. Other antibiotics like doxycycline and ciprofloxacin may be used orally. Symptomatic and supportive care is also provided to manage the various symptoms of the disease. In some cases, treatment may need to be monitored closely, especially if symptoms began before antibiotic therapy was initiated, as there is a risk of relapse. The duration of treatment typically lasts for 10 to 21 days, but full recovery may take longer. It is essential to seek medical attention promptly, as untreated cases of tularemia can have severe complications, including organ damage, and up to 30% of untreated cases of type A tularemia can be fatal.

"Tularemia - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tularemia pipeline landscape is provided which includes the disease overview and Tularemia treatment guidelines. The assessment part of the report embraces, in depth Tularemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tularemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Tularemia R&D. The therapies under development are focused on novel approaches to treat/improve Tularemia.

Tularemia Emerging Drugs Chapters

This segment of the Tularemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tularemia Emerging Drugs

ATI-1701: Appili Therapeutics

ATI-1701 is the Company’s potential first-in-class vaccine candidate for the prevention of infection with F. tularensis, the causative agent of tularemia and a top-priority biothreat. Appili is developing ATI-1701 as a vaccine to combat F. tularensis, which is classified by the U.S. National Institutes of Health (NIH) as a Category A pathogen, an organism that poses the highest risk to national security and public health. The drug is currently in the preclinical stage of development for the treatment of patients with Tularemia.

Tularemia: Therapeutic Assessment

This segment of the report provides insights about the different Tularemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Tularemia

There are approx. 3+ key companies which are developing the therapies for Tularemia. The companies which have their Tularemia drug candidates in the most advanced stage, i.e. Preclinical include, Appili Therapeutics.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Tularemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tularemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tularemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tularemia drugs.

Tularemia Report Insights

• Tularemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tularemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tularemia drugs?
• How many Tularemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tularemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tularemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tularemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Appili Therapeutics
• Wakunaga Pharmaceutical

Key Products

• ATI-1701
• Delafloxacin

This product will be delivered within 2 business days.